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Introduction {#sec1}
============

RNA molecules lacking 5′ and 3′ ends and shaped as covalently closed circular RNAs (circRNAs) were described decades ago in a variety of model systems, but they were considered rare events ([@bib37], [@bib5]). However, recent studies report that these molecules are commonly produced by thousands of genes ([@bib36], [@bib23], [@bib30]) and are usually generated by the joining of a 5′ splice site with the 3′ splice site of an upstream intron, in a so-called back-splicing reaction ([@bib17], [@bib2], [@bib38], [@bib11]). It has been shown that circRNA expression is often highly conserved across species and particularly abundant in mammalian neuronal tissues ([@bib35]). Moreover, the DNA that encodes circRNAs is more conserved than the DNA of flanking exons ([@bib35]). Very little is known about their mechanism of action; some may be sponges for microRNAs (miRNAs), as shown for CDR1as and SRY in vertebrate neuronal tissues ([@bib30], [@bib18]) and for circ-HIPK3 in human cancers ([@bib50]). Nevertheless, genome-wide studies have demonstrated that miRNA sponging activity cannot be generally applied ([@bib30], [@bib48], [@bib22]), and other mechanisms have also been proposed, such as acting as platforms for protein interaction ([@bib19]). This specifically pertains to circ-Mbl, which competes for the splicing of its linear counterpart by binding to Mbl ([@bib2]), and to circ-Foxo3, which blocks cell-cycle progression by interacting with Cdk ([@bib14]). Emerging evidence also suggests a potential role of circRNAs in different human diseases ([@bib9]), with data indicating tumor-promoting properties in in vivo models ([@bib16]). Despite these data in favor of circRNAs' relevant functional roles, their impact on biological processes is still largely unexplored.

In this work, we have identified conserved circRNAs that are regulated during murine and human muscle differentiation and whose expression is altered in Duchenne muscular dystrophy (DMD) myoblasts. A dedicated knockdown strategy followed by a high-content phenotypic screening identified circRNAs' participation in the control of myogenesis; circ-ZNF609, selected on the basis of its ability to regulate myoblast proliferation, provided an interesting example of translation occurring on a circRNA.

Results {#sec2}
=======

CircRNAs Are Abundant, Conserved, and Highly Expressed {#sec2.1}
------------------------------------------------------

Total RNA was collected from two replicates of human and mouse (C~2~C~12~) myoblasts cultured in growth medium (GM) or induced to differentiate into myotubes (differentiation medium, DM). Paired-end ribominus RNA sequencing (RNA-seq) was performed, and the FindCirc computational pipeline ([@bib30]) was applied in order to detect circRNAs. RNA-seq data were first processed for gene expression analysis: reads were mapped with TopHat and the transcriptome was reconstituted with Cufflinks (data summarized in [Figure S1](#mmc1){ref-type="supplementary-material"}A). Differential gene expression analysis was performed in order to check the quality of the in vitro differentiation experiments. While fragments per kilobase of transcript per million mapped reads (FPKMs) of genes in technical replicates were almost perfectly correlated (\>98% correlation; [Figure S1](#mmc1){ref-type="supplementary-material"}B, upper panels), gene expression in myotubes compared to myoblasts was highly diverse, with \>3,000 genes significantly upregulated or downregulated in one of the two conditions, in both human and mouse systems ([Figure S1](#mmc1){ref-type="supplementary-material"}B, lower panels). When looking at the enrichment of gene products upregulated in myotubes versus myoblasts in terms of gene ontology (GO) biological process keywords, we found a consistent and significant enrichment for genes related to muscle differentiation and function ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Moreover, the expression of well-known specific markers of muscle differentiation was assessed by qRT-PCR, which confirmed the data obtained by RNA-seq ([Figure S1](#mmc1){ref-type="supplementary-material"}D).

RNA-seq reads were then realigned to the reference genomes, the ones contiguously aligned were discarded, and the remaining reads were used as input for FindCirc ([Figure 1](#fig1){ref-type="fig"}A) to detect head-to-tail splicing sites. As described in [Figure 1](#fig1){ref-type="fig"}B, thousands of circular splicing events were found in both human and mouse samples, with almost 90% deriving from internal exons of protein-coding genes ([Figure 1](#fig1){ref-type="fig"}C). Almost 10% of circRNAs was expressed at similar or higher levels with respect to the linear counterpart (by comparing the number of reads mapping on circular versus linear splice junctions). Interestingly, almost 600 of these circRNAs were conserved between species of the ∼2,100 and 1,600 circRNAs identified in human and mouse, respectively ([Figure 1](#fig1){ref-type="fig"}D, full list in [Table S1](#mmc2){ref-type="supplementary-material"}). Our criterion for conservation was any circRNA in which the genomic location in human overlapped with the syntenic region in mouse. Considering that low-abundance species might have been missed by this analysis, the actual species overlap may be even higher. Indeed, when filtering human circRNAs for high expression level (more than five reads), the overlap with mouse circRNAs increased from ∼25% to 40%.

CircRNA Expression Is Modulated in Muscle Differentiation and Disease {#sec2.2}
---------------------------------------------------------------------

To perform quantitative analyses on circRNA expression and regulation, we took human samples and reduced further our list to a set of highly expressed molecules by requiring at least five unique reads mapping to the head-to-tail junction. With this threshold, while the technical replicates had an overall very good correlation ([Figure 2](#fig2){ref-type="fig"}A), the comparison between myoblasts and myotubes revealed a global change in circRNA expression (∼45% circRNAs having ≥2-fold variation in one of the two conditions, [Figure 2](#fig2){ref-type="fig"}B), meaning that these molecules were modulated in response to cell differentiation. RNA-seq data from human myoblasts derived from DMD patients were also analyzed. Hierarchical clustering analysis of normal and dystrophic myoblasts and myotubes revealed that indeed DMD cells have a unique signature in terms of circRNA expression levels ([Figure 2](#fig2){ref-type="fig"}B): specific subsets of transcripts were differently abundant in DMD with respect to controls both in GM and in DM conditions. This is in agreement with the notion that Duchenne cultures have a much slower progression into the differentiation process ([@bib6]). Notably, circRNA abundance tends in general to increase during differentiation ([Figure 1](#fig1){ref-type="fig"}B), as described for neuronal differentiation ([@bib35]). The circular/linear ratio also followed this trend ([Figures 2](#fig2){ref-type="fig"}C and 2D). This is possibly related to the high stability of these molecules: during differentiation, induction of circRNAs at the transcriptional level, combined with a slow turnover, could lead to their accumulation over time.

Then we addressed the question of whether modulation of circRNA expression in myogenesis was due to transcriptional regulation of the host gene or to post-transcriptional control, such as competitive biogenesis between the linear and the circular isoforms within the same gene ([@bib2]). Therefore, we analyzed the relationship between the fold change ratio of circular versus linear expression level in the two conditions tested (GM versus DM), and we found a positive correlation ([Figure 2](#fig2){ref-type="fig"}E). Additionally, according to FPKMs calculated with Cuffdiff, the abundance of circRNAs produced from upregulated, stable, or downregulated genes indicated that the induction of circRNAs coming from upregulated genes was significantly higher than that of stable and downregulated genes ([Figure 2](#fig2){ref-type="fig"}F). However, exceptions were detected, such as the BNC2 gene that produces mainly the linear mRNA in human and mouse myoblasts in growth conditions but predominantly the circRNA in differentiated cells. [Figure 2](#fig2){ref-type="fig"}G shows circ-BNC2 in comparison with circ-CDYL, which is an example of a concomitant increase in both circular and linear isoforms during myogenesis, probably because of transcriptional activation of the locus.

RNAi-Based CircRNA Functional Screening {#sec2.3}
---------------------------------------

Specific criteria were applied in order to restrict the number of candidates for further characterization: (1) conservation, (2) expression level, (3) modulation during differentiation, and (4) circular/linear ratio (see the [STAR Methods](#sec4){ref-type="sec"}). This filtering yielded 31 circRNAs, which are shown in [Table 1](#tbl1){ref-type="table"}. The selected species were initially validated by RT-PCR (summarized in [Table 1](#tbl1){ref-type="table"}, full results in [Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B, list of primers in [Table S2](#mmc3){ref-type="supplementary-material"}). Of 31 candidates, only one, circ-MYL4, was not detected as a band of the expected size in human samples. Circ-TTTY16 was instead not detected in mouse samples, because it is located in the Y chromosome, which is not present in C~2~C~12~ cells. For almost every circRNA, RT-PCR produced a band of the expected size and one or more larger products, possibly corresponding to concatemers generated by rolling circle retro-transcription. For a few circRNAs (CDYL, QKI, and ZNF609), we gel-extracted and sequenced those bands, confirming that they contained the head-to-tail junction and that they were concatemers ([Figure S2](#mmc1){ref-type="supplementary-material"}C). The qRT-PCR analysis of a subset of six human circRNAs did not reveal a major second PCR product for any of them ([Figure S2](#mmc1){ref-type="supplementary-material"}D), possibly because of the different enzyme and cycling conditions used with respect to non-quantitative PCR and opening to the possibility of using such technique for accurate measurement of relative circRNA expression ([Figure S2](#mmc1){ref-type="supplementary-material"}E). Indeed, in all cases, the normalized RNA quantities measured by qRT-PCR reflected the levels observed by RNA-seq and RT-PCR ([Figure S2](#mmc1){ref-type="supplementary-material"}E). For the same candidates, purification of total RNA with oligo dT revealed that they were preferentially recovered in the non-polyadenylated fraction with respect to their linear counterparts ([Figure S2](#mmc1){ref-type="supplementary-material"}F). Similarly, comparison of dT- versus random examer-primed cDNA synthesis shows that circRNAs were retro-transcribed more efficiently with random examers than with dT with respect to linear RNAs ([Figure S2](#mmc1){ref-type="supplementary-material"}G).

Resistance to the RNase R exonuclease was used to test whether the selected molecules were circular ([@bib39]). Of 30 putative circRNAs, 29 were confirmed as non-accessible to the exonuclease. Only one, circ-NEB, was digested by RNase R as efficiently as its linear counterpart (summarized in [Table 1](#tbl1){ref-type="table"}, full results in [Figures S2](#mmc1){ref-type="supplementary-material"}H and S2I). Moreover, nuclear/cytoplasmic fractionation indicated that all circular species were almost exclusively located in the cytoplasm, both in mouse and human cells ([Figures S2](#mmc1){ref-type="supplementary-material"}J and S2K).

We then designed an image-based functional genetic screen to further characterize these molecules (summarized in [Figure 3](#fig3){ref-type="fig"}A). We tried to design at least two small interfering RNAs (siRNAs) targeting each of the 29 circRNAs, according to the following features: (1) binding site at the head-to-tail junction; (2) 7-mer seed not present in the linear host gene; and (3) chemical modifications within the seed region, in order to reduce the chance of an miRNA-like effect and passenger strand inactivation to direct strand-specific Ago loading. These modifications and their applications have been the objective of extensive studies ([@bib21], [@bib8]), and they have been here designed for customized targets (On-Target-plus by Dharmacon). Following these rules, it was possible to design two siRNAs for 20 circRNAs, one for five circRNAs, and none for the four remaining ones ([Figure S3](#mmc1){ref-type="supplementary-material"}A; siRNAs listed in [Table S3](#mmc4){ref-type="supplementary-material"}). Due to the poor transfectability of human primary myoblasts, we developed a reverse transfection protocol that allowed high-efficiency transfection of siRNAs in these cells (see the [STAR Methods](#sec4){ref-type="sec"}). The 45 siRNAs plus a negative control were applied in triplicate to myoblast cultures in a 96-well format, and, 24 hr post-transfection, cells were switched to DM for 48 and 96 hr. The relative abundance of the circular versus linear forms was tested in order to confirm the specific downregulation of the circRNA. This revealed that at least one siRNA for 17 different genes specifically downregulated the circular form without affecting the linear mRNA ([Figure S3](#mmc1){ref-type="supplementary-material"}B).

Immunofluorescence analysis was performed for two common myogenic markers, Myogenin (MYOG) and Myosin Heavy Chain (MHC), together with DAPI staining ([Figure S3](#mmc1){ref-type="supplementary-material"}C). Several readouts were analyzed in order to obtain a detailed picture of how knockdown of each circRNA affected cell differentiation and morphology. We included in this analysis 11 different phenotypes, including total cell number, the fraction of MYOG- or MHC-positive cells, and additional morphological parameters, such as the fusion index. From this screening, two strong and opposite phenotypes associated with siRNAs targeting circ-QKI and BNC2 emerged. The two siRNAs designed for circ-QKI (siRNA \#1 and siRNA \#2) both inhibited myoblast differentiation ([Figure 3](#fig3){ref-type="fig"}B). While siRNA \#1 had a specific effect on circ-QKI and none on QKI mRNA, siRNA \#2 did not alter circ-QKI levels but downregulated QKI mRNA ([Figure S3](#mmc1){ref-type="supplementary-material"}B). This supports the hypothesis that both circ-QKI and QKI mRNA participate in the same process. To confirm that hypothesis, we raised a third siRNA specifically targeting QKI mRNA (si-QKI-L; [Figure S3](#mmc1){ref-type="supplementary-material"}D). si-QKI-L, and additional experimental replicates with si-QKI \#1 ([Figures 3](#fig3){ref-type="fig"}C, [S3](#mmc1){ref-type="supplementary-material"}B, S3D, and S3E), had again a specific anti-myogenic effect, thus confirming that both the circRNA and the mRNA could be involved in promoting differentiation ([Figure S3](#mmc1){ref-type="supplementary-material"}E, as in [@bib29]).

In the case of circ-BNC2, si-BNC2 \#1 efficiently downregulated circ-BNC2 but had also a small effect on BNC2 mRNA, while si-BNC2 \#2 targeted specifically circ-BNC2 and had no effect on the phenotype ([Figure S3](#mmc1){ref-type="supplementary-material"}B). These data suggested that the observed phenotype was likely associated with BNC2 mRNA knockdown. We confirmed this by using a third siRNA, designed specifically for BNC2 mRNA (si-BNC2-L; [Figures S3](#mmc1){ref-type="supplementary-material"}D and S3E), and we observed the same effect as with additional replicates of si-BNC2 \#1 ([Figures 3](#fig3){ref-type="fig"}C, [S3](#mmc1){ref-type="supplementary-material"}D, and S3E). Notably, during differentiation, a strong increase of the circular RNA paralleled the decrease of the linear BNC2 mRNA ([Figures 2](#fig2){ref-type="fig"}G, [S2](#mmc1){ref-type="supplementary-material"}A, and S2B). Therefore, it is likely that biogenesis of circ-BNC2 is a mechanism for competing with the production of the anti-myogenic BNC2 mRNA when differentiation starts.

Interestingly, both circRNAs, upregulated during in vitro differentiation of control myoblasts, were downregulated in DMD conditions ([Figure 3](#fig3){ref-type="fig"}D), well correlating with the notion that dystrophic cells have altered progression into the differentiation process ([@bib6]). For a different set of circRNAs highly expressed in myoblasts, we investigated the relationship between their abundance and proliferation capacity through a bromodeoxyuridine (BrdU)-labeling assay ([Figure S3](#mmc1){ref-type="supplementary-material"}C). Among the circRNAs tested, we found that the knockdown of circ-ZNF609 (successfully accomplished with siRNA \#1) reduced BrdU incorporation by ∼80% ([Figure 4](#fig4){ref-type="fig"}A). In line with this, also markers of proliferation, such as CDK1 and cyclin A2, were significantly reduced after circRNA knockdown ([Figure 4](#fig4){ref-type="fig"}E), indicating a specific role of circ-ZNF609 in myoblast proliferation. Similar effects, even if at lower extents, were observed in murine cells ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B). The initial screening was subsequently validated by comparing the activity of three distinct siRNAs: si-circ (corresponding to siRNA \#1 used in the screening), which targets the circ-ZNF609 head-to-tail junction; si-ex2, targeting both the circRNA and its linear counterpart; and si-mRNA targeting only the linear mRNA ([Figure 4](#fig4){ref-type="fig"}B). Both si-circ and si-ex2 reduced myoblast growth rate by 80% while si-mRNA, targeting only the linear mRNA, did not affect proliferation ([Figures 4](#fig4){ref-type="fig"}C and 4D). These results allowed us to exclude that the observed phenotype was due to an off-target effect, and they indicated that the decrease in proliferation was solely due to the circRNA activity. Both circular and linear ZNF609 RNA levels were measured after treatments by qRT-PCR, confirming the specificity of the three siRNAs ([Figure 4](#fig4){ref-type="fig"}E). Moreover, northern blot analysis confirmed that circ-ZNF609 was susceptible to si-circ treatment and resistant to RNase R ([Figure 4](#fig4){ref-type="fig"}F), while the linear ZNF609 mRNA was resistant to si-circ and susceptible to RNase R ([Figure 4](#fig4){ref-type="fig"}F). Notably, the circular form co-migrated with the product derived from an artificial construct, p-circ (see next paragraph), overexpressing circ-ZNF609 RNA ([Figure 4](#fig4){ref-type="fig"}F).

Also interestingly, circ-ZNF609, which is downregulated during myogenesis in control myoblasts, was instead found at elevated levels in DMD conditions ([Figure 4](#fig4){ref-type="fig"}G). This is consistent with the delayed differentiation phenotype of dystrophic primary myoblasts and with the persistence of a high proportion of proliferating, non-fusing myoblasts ([@bib6]). These data reinforce further the connection of circ-ZNF609 and myoblast proliferation.

Circ-ZNF609 Encodes a Protein {#sec2.4}
-----------------------------

Circ-ZNF609 originates from the circularization of the second exon of its host gene. A 753-nt open reading frame (ORF) is present in circ-ZNF609, spanning from the putative AUG of the host gene to a STOP codon created 3 nt after the splice junction ([Figure 5](#fig5){ref-type="fig"}A). To determine whether this ORF (circORF) is functional, we first used sucrose gradient fractionation to test circ-ZNF609 loading onto polysomes. [Figure 5](#fig5){ref-type="fig"}B shows that a small but significant proportion of circ-ZNF609 sedimented with heavy polysome fractions while the rest remained in the non-bound fraction. The circular conformation of the polysome-bound circ-ZNF609 RNA was confirmed by RNase R resistance ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B). Moreover, we excluded the presence of possible linear concatemers by northern blot ([Figure 4](#fig4){ref-type="fig"}F; see also RT-PCR with primers in exons 1 and 3 of the ZNF609 gene in [Figure S5](#mmc1){ref-type="supplementary-material"}C). In puromycin-treated myoblasts, circ-ZNF609 shifted to lighter polysomes, similarly to the behavior of the linear ZNF609 and HPRT mRNAs, suggesting that its sedimentation pattern was due to active translation. As a control, a circRNA with no ORF, circ-PMS1, remained on free RNA fractions. The association of circ-ZNF609 with heavy polysomes was also confirmed in mouse ([Figure S5](#mmc1){ref-type="supplementary-material"}D).

To test the protein-coding ability of circ-ZNF609, we took advantage of an expression vector that was able to produce circular transcripts ([@bib26]). P-circ contains the second exon of the ZNF609 gene and is able to express circ-ZNF609 RNA at high levels ([Figure 4](#fig4){ref-type="fig"}F). Sequencing of the RNA produced from this construct revealed its perfect correspondence with the endogenous circ-ZNF609 RNA (data not shown). A construct was derived from p-circ that contained a 3×FLAG-coding sequence immediately upstream of the STOP codon, such that a flagged protein could be produced only upon formation of a circular template (p-circ3xF; [Figure 6](#fig6){ref-type="fig"}A). Due to the poor transfection efficiency of plasmid DNA in human and murine myoblasts, the following experiments were carried out in HeLa and N2A cells. The results indicate that in both cell types, in comparison to mock-treated cells, p-circ3xF gave rise to two flagged proteins ([Figure 6](#fig6){ref-type="fig"}B). Inspection of the sequence indicated that a second ATG codon was present 150 nt downstream of the first one and in the same frame. Mutants lacking either one of the two initiation codons (p-circΔ1 and p-circΔ2) showed that two bands observed by western blot corresponded to two isoforms: the upper band (ATG1) derived from translation from the first ATG, while the lower one (ATG2) originated from the second start codon ([Figure 6](#fig6){ref-type="fig"}B). Deletion of both ATGs (p-circΔ1-2) abolished both products. An additional mutant, with a TGA Stop codon replacing ATG2 ([Figure 6](#fig6){ref-type="fig"}A; STOP2), confirmed that translation of the flagged proteins required initiation at those precise sites ([Figure S6](#mmc1){ref-type="supplementary-material"}C).

An additional construct, p-lin3xF, was raised carrying the same ORF present in circ-ZNF609 in a linear conformation. When transfected in HeLa and N2A cells, this plasmid induced the expression of the same two proteins observed with the circular substrate, even if with a much higher efficiency ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B). Moreover, the flagged protein resulted in nuclear localization ([Figure S6](#mmc1){ref-type="supplementary-material"}C). Titration of the proteins produced by the linear versus the circRNAs, normalized for the amount of RNA produced, indicated that circRNA was translated at almost two orders of magnitude lower efficiency than the linear form ([Figure S6](#mmc1){ref-type="supplementary-material"}B). These results are in line with previous observations showing that re-initiation and internal initiation of translation can be as low as 1%--10% the efficiency of cap-dependent initiation ([@bib31]). Moreover, while the circular template yielded approximately the same amount of the two isoforms, translation of the linear one was strongly biased in favor of the first ATG, indicating a substantial difference in the translation initiation mechanism between the circular and linear transcripts.

In cells expressing p-circ3xF and the different ATG mutant derivatives, we confirmed the production of circular transcripts by northern analysis ([Figure S6](#mmc1){ref-type="supplementary-material"}D), with a specific control of RNase R resistance ([Figure S6](#mmc1){ref-type="supplementary-material"}E). We also verified the integrity of the ORF by Sanger sequencing of the RT-PCR products (data not shown), and we further excluded the production of linear concatemers through RT-PCR ([Figures S6](#mmc1){ref-type="supplementary-material"}F and S6G).

To further prove the protein-coding ability of the circ-ZNF609 RNA derived from the chromosomal gene, we designed a genome-editing approach for inserting the 3×FLAG-coding sequence in the endogenous ZNF609 locus. We used the CRISPR/Cas9 system in mouse embryonic stem cells in combination with a DNA donor designed for inserting the 3×FLAG-coding sequence in the same position as in p-circ3xF, so that a flagged protein could be produced only upon circularization of the second exon of ZNF609 ([Figure 6](#fig6){ref-type="fig"}D). After transfection, clonal selection, and genotypization ([Figures S6](#mmc1){ref-type="supplementary-material"}H--S6J), we obtained one positive clone carrying two modified alleles: the first one contained the expected flagged allele, while the second carried a small deletion across the 3′ splice site of the first intron, which prevented circularization of the second exon ([Figure S6](#mmc1){ref-type="supplementary-material"}J; F/D clone). Therefore, from this cell line only the flagged allele would be able to produce the circ-ZNF609 RNA, and the amount of circRNA produced would be half of that produced by a wild-type (WT) line. Since circ-ZNF609 is highly expressed in neural tissues ([@bib35]), we applied an established neuronal differentiation protocol ([@bib46]), and we checked for the expression of the FLAG-tagged circ-ZNF609 RNA by northern blot in WT cells and in the F/D clone. As expected for their genomic context, F/D cells produced roughly half the circRNA of WT cells ([Figure S6](#mmc1){ref-type="supplementary-material"}K); moreover, the circRNA was slightly larger than in the WT because of the inserted tag. RT-PCR and Sanger sequencing confirmed that the circ-ZNF609 RNA produced by F/D cells was identical to that made by the p-circ3xF construct. Due to the low translation efficiency and the high background in western analysis, we performed immunoprecipitation of F/D cells lysates with an anti-FLAG antibody, and then we subjected proteins (size selected between 30 and 40 kDa) to mass spectrometry on a polyacrylamide gel. As positive controls, we immunoprecipitated proteins from cells transfected with the constructs overexpressing either the linear or the circular flagged ORF. [Figure 6](#fig6){ref-type="fig"}E shows that numerous peptides, mapping to the circORF, were present in overexpression conditions with the linear construct (p-lin3xF), fewer with overexpression of the p-circ3xF construct, and one in the F/D sample. This is in agreement with the lower levels of RNA produced by the chromosomal gene, with respect to those obtained with the overexpression of both p-circ3xF ([Figure 4](#fig4){ref-type="fig"}F) and p-lin3xF, and to the lower translational efficiency from circular templates ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B). No ZNF609 peptides were instead detected in control WT cells.

As low initiation efficiency is commonly associated with cap-independent translation, which instead serves as a regulatory mechanism responding to various external stimuli, such as heat shock stress ([@bib20]), we tested protein production in such condition. As shown in [Figure 6](#fig6){ref-type="fig"}F, heat shock induces a strong and significant increase in translation of the flagged circ-ZNF609 transcript.

IRES Activity of Circ-ZNF609 UTR {#sec2.5}
--------------------------------

Since circRNAs are devoid of cap structure, translation should occur through sequences able to act as internal ribosome entry sites (IRESs). Notably, phylogenetic analysis of the 5′ and 3′ UTRs of ZNF609 in vertebrates indicated that the portion of the 5′ UTR present in circ-ZNF609 was significantly more conserved than the other UTR sequences situated in the linear ZNF609 mRNA ([Figure S6](#mmc1){ref-type="supplementary-material"}L). To test whether it possessed IRES-like activity, the circ-ZNF609 UTR was inserted between the Firefly and Renilla luciferases of a bicistronic construct (UTR; [Figure 6](#fig6){ref-type="fig"}G). With respect to a vector containing a viral IRES sequence (EMCV), UTR displayed very little luciferase activity ([Figure 6](#fig6){ref-type="fig"}H). Remarkably, Renilla luciferase raised to levels even higher than those of EMCV when introns from ZNF609 (UTR-inZNF), HPRT (UTR-inHPRT), and β-globin (UTR-inβglob) genes were inserted into the UTR construct, reconstituting the original splice junction of circ-ZNF609. Furthermore, deletion of the 5′ splice site in UTR-inβglob (UTR-Δss) completely abolished luciferase levels ([Figure 6](#fig6){ref-type="fig"}H), indicating that Renilla luciferase (Rluc) activity did not originate from cryptic splice sites and ultimately proving the relevance of splicing in the induction of IRES activity. Finally, the circ-ZNF609 UTR was replaced with an unrelated sequence of similar length (MCS-inβglob). Notably, this construct was not able to trigger Rluc activity ([Figures 6](#fig6){ref-type="fig"}G and 6H), thus pointing out that IRES activity also relies on specific features of the UTR sequence. RT-PCR analysis indicated that correct splicing, where applicable, was obtained for all constructs ([Figure S6](#mmc1){ref-type="supplementary-material"}M). Altogether, these data show that the UTR of circ-ZNF609 is able to work as an IRES in a splicing-dependent manner.

Moreover, synthetic FLAG-tagged circ-ZNF609 made by in vitro ligation ([Figure S6](#mmc1){ref-type="supplementary-material"}N) was not translated upon transfection in comparison to the same molecule produced through back-splicing from plasmid p-circ3xF, further demonstrating the requirement of a splicing-dependent process for efficient circRNA translation ([Figures S6](#mmc1){ref-type="supplementary-material"}N and S6O).

Discussion {#sec3}
==========

Due to several unique features, circRNAs are increasingly recognized as promising candidates for the identification of additional layers of gene expression control. For instance, circRNAs can pleiotropically modulate gene expression by competing for miRNA or protein binding ([@bib18], [@bib19], [@bib14]), or they can compete with linear RNA production regulating the accumulation of full-length mRNA ([@bib2]). They have been shown to have differential tissue-specific expression ([@bib30], [@bib35]) and specific subcellular localization ([@bib35], [@bib48]). Despite the large number of circRNAs identified in many different organisms, tissues, and developmental conditions, only a few examples are available that indicate a crucial role on cellular functions ([@bib16], [@bib47]). In part this is due to the difficulty in selective targeting of circRNAs, because their nature limits the choice of target region for selectivity and further constrains the parameters normally used for designing mRNA-targeting siRNAs.

Here, with a combination of bioinformatic tools, we obtained selective circRNA downregulation using modified siRNAs. These reagents were used in an image-based functional genetic screen of 25 circRNA species, conserved between mouse and human, which were differentially expressed during myogenesis. Such analysis provided one interesting case, circ-ZNF609, whose phenotype could be specifically attributed to the circular form and not to the linear counterpart. Notably, analysis of the circ-ZNF609 sequence revealed the presence of an ORF. We found that a fraction of circ-ZNF609 RNA is loaded onto polysomes and that, upon puromycin treatment, it shifted to lighter fractions, similar to canonical mRNAs. The coding ability of this circRNA was proved through the use of artificial constructs expressing circular tagged transcripts and by CRISPR/Cas9 tagging of the endogenous ZNF609 gene. Proteins derived from the translation of circRNAs were described a long time ago in Archaea, where homing endonucleases were produced by stable circularized introns ([@bib24], [@bib12]). Although there are reports of circRNA in vitro translation ([@bib7]) and of proteins derived from artificial circRNA constructs ([@bib43], [@bib1]), our data demonstrate that an eukaryotic endogenous circRNA may encode for a protein.

Generation of protein isoforms via back-splicing and circularization of selected exons from primary mRNA transcripts is an intriguing mechanistic alternate to conventional alternative splicing. Interestingly, termination codons present upstream of the AUG initiation codon in linear mRNAs can be converted into in-frame STOP codons upon circularization. Moreover, depending on the distance of the STOP codon from the newly formed junction, peptides with additional amino acids that are absent from the linear form can be produced. Therefore, these mechanisms enlarge the repertoire of protein domains that can be derived from a primary transcriptional unit, and they increase further the complexity of the genome output. This is particularly interesting in consideration of the fact that many circRNAs contain the canonical start codon of their host gene (735 circRNAs of 2,175 in our human dataset, well above the number expected by chance).

So far, we have no hints on the molecular activity of the proteins derived from circ-ZNF609 and as to whether they contribute to modulate or control the activity of the counterpart deriving from the linear mRNA. The zinc-finger protein 609 has been described as a transcriptional factor characterized by two zinc-finger domains. To date only limited information is available about its activity. It was detected as part of a protein interaction network dedicated to control embryonic stem cell (ESC) pluripotency in Nanog-associated complexes ([@bib15]) and as a direct interactor of Dax1 ([@bib44]). ZNF609 was also shown to be required for Rag1 and Rag2 expression in developing thymocytes ([@bib34]). The fact that the circ-ZNF609-encoded protein lacks the zinc-finger domains would suggest different hypotheses on how it could interfere or cope with the activity of the full-length isoform: it could act as a dominant-negative competitor or as a modulator of alternative ZNF609 complex formation. Interestingly, the flagged protein derived from circ-ZNF609 exhibited mainly nuclear localization.

However, since the use of plasmids and other expression vectors as well as naked RNA produced a non-specific block of myoblast proliferation, we were unable to perform rescue experiments and univocally link the circ-ZNF609 phenotype to its protein-coding capacity.

Another relevant aspect about circRNAs, lacking the cap structure and the polyA tail, relates to the machinery and factors required for the assembly into translationally competent complexes. Cap-independent translation, driven by the so-called IRES, was initially described in viral RNAs ([@bib33]) and subsequently identified also in cellular RNAs ([@bib45]). IRESs can act by various mechanisms, including the formation of RNA structures, Watson-Crick base pairing with the 18S ribosomal RNA, and often in cooperation with IRES-transacting factors (ITAFs) ([@bib25]); moreover, putative cellular IRESs have been suggested to play crucial roles in different developmental conditions and in response to different types of stress ([@bib20]).

In this work, we showed that the UTR element of circ-ZNF609, spanning from the termination to the initiation codons, can drive IRES-dependent translation but only if produced through a splicing event, suggesting that factors loaded on the transcript upon splicing might play a crucial role in ribosome recognition and translation initiation.

In this study, we have also observed that the circular template had a much lower translation activity when compared to the linear counterpart, a feature exhibited also when analyzing the cell line carrying an endogenous flagged allele obtained through CRISPR/Cas9 genome editing. Interestingly, heat shock induced significant activation of the flagged circ-ZNF609 translation. It is well known that cap-independent initiation is less efficient than the cap-dependent one ([@bib31]) and that regulation of cap-independent translation is often used to respond to several cellular stresses in order to allow immediate and selective changes in protein levels ([@bib20]). Along this line, *cis*-acting elements have been also shown to respond to different cellular stresses and to contribute in the promotion of translation initiation through a cap-independent mechanism. This is the case of N6-methyladenosine (m6A) residues whose levels in 5′ UTRs are increased upon different cellular stresses ([@bib51], [@bib32]). Notably, reanalysis of m6A cross-linking and immunoprecipitation (CLIP) data ([@bib49]) and m6A immunoprecipitation (IP) in myoblasts ([Figures S6](#mmc1){ref-type="supplementary-material"}P and S6Q) revealed that circ-ZNF609 is highly methylated, suggesting a possible regulatory role of this modification in circ-ZNF609 translational activity.

In conclusion, circ-ZNF609 provides relevant material to identify the factors required for the translation of this class of transcripts devoid of cap and polyadenylated tails. Further work will be required in order to understand whether circRNA translation responds to specific stimuli or signals different from those regulating protein synthesis conducted by linear mRNAs.
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Irene Bozzoni (<irene.bozzoni@uniroma1.it>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Cell culture and treatments {#sec4.3.1}

Mouse myoblasts (C~2~C~12~, ATCC) were cultured in Growth Medium (GM, DMEM with 20% FBS, L-Glutamine 2 mM and Penicillin/Streptomycin) and induced to differentiate in DM (FBS reduced to 0.5%). Human myoblasts (WT and DMD) were cultured in Growth Medium (GM, DMEM with 10% FBS, L- Glutamine 2 mM, insulin 50 mg/ml, FGFb 25 ng/ml, EGGF 1 ng/ml, Penicillin/Streptomycin) and induced to differentiate with Human Skeletal Muscle DM (Promocell).

Reverse transfection of human myoblasts with siRNAs was performed as follows: 96-well optical plates (Corning) were treated overnight with 350 mg of Collagen Type I in water and 0.5% acetic acid, washed with PBS and UV-sterilized. Twenty microliters of siRNA transfection mix (150 nM siRNA, 0.2 μL Dharmafect lipid reagent from Dharmacon, 20ml transfection medium: DMEM with L-glutamine 2mM and insulin 50 mg /ml) was seeded in each well, left at RT for 20 min and then diluted with 30 μL of transfection medium. Cells (12000 per well) were added after resuspension in double complete medium (GM with 2X concentration of serum, antibiotics, FGFb and EGF). Cells were switched to DM after 24h and fixed or collected for analysis at 48 hr and 96 hr.

HeLa and N2A cells were cultured in DMEM with 10% FBS, L-Glutamine 2 mM and Penicillin/Streptomycin 1X. HeLa and N2A cells were transfected with 2 μg of plasmid DNA with Lipofectamine 2000. Two μl of lipofectamine were added to 300 μL of Optimem with DNA, mixed and pipetted in a 35-mm plate with 200000 cells. Medium was replaced 4 hr later and cells harvested for protein and RNA analyses after 48 hr. For heat shock experiments, p-circ3xF-tranfected HeLa cells were cultured at 44°C for three hours.

Method Details {#sec4.4}
--------------

### RNA isolation, treatments and analysis {#sec4.4.1}

Total RNA in this study was extracted with Qiazol reagent according to the manufacturer's protocol (QIAGEN). RNA from 96-well plates and nuclear/cytoplasmic fractions was purified with miRNEasy spin columns according to the manufacturer's specifications (QIAGEN).

RNase R treatment was performed as follows: 1-10 μg of total RNA was diluted in 20 μL of water with 4u RNase R/μg unless differently stated and 2 μL of enzyme buffer (Epicenter), then incubated 15 min at 37°C and purified by phenol chloroform extraction. One pg of a DNA spike- in molecule was added to each reaction for qPCR normalization. DNA spike-in was produced from the multiple cloning site in pcDNA3.1(-) (Life technologies).

Retrotranscription of RNA in this study was performed with VILO Superscript (Life Technologies): up to 2 μg of RNA were retrotranscribed in a 10 μL reaction mix with 1 μL of enzyme and 2 μL of buffer, incubated 10 min at 25°C, 60 min at 42°C and 5 min at 85°C. qRT-PCR analyses in this study were performed as follows: cDNA (2-10 ng equivalent) was added to a reaction composed of 7.5 μL 2X SYBR Mastermix (QIAGEN), 1.5 μL of 5 mM primers and water to a final volume of 15 μl. DNA amplification (40 cycles of 95°C for 30 s, 55°C for 30 s and 72°C for 30 s, followed by melting curve analysis) was monitored with an ABI 7500 Fast qPCR instrument.

RT-PCR for circRNA detection was performed with 0.2 μL of Mytaq DNA polymerase (Bioline) in 25 μL water with 5 μL reaction buffer, 15 ng of cDNA, 2.5 μL 5mM primers. Reaction was carried out for 28 cycles at 95°C for 25 s, 55°C for 25 s, 72°C for 25 s. Five microliters of PCR were run on 2% agarose gels. All primers used in this study are reported in [Table S2](#mmc3){ref-type="supplementary-material"}. RT-PCR for circular and linear RNA from the same locus was carried out for the same number of cycles.

### Northern blots {#sec4.4.2}

RNA (10-20 μg for detection of endogenous circRNA and 1-2 μg for detection of overexpressed circRNA) was denatured with one volume of glyoxal loading dye (Ambion) for 30' at 50°C and loaded on 1.2% agarose gel. Electrophoresis was carried out for 2-3 hr at 60 V. RNA was transferred on Hybond N+ membrane (GE Healthcare) by capillarity overnight in 10X SSC. Transferred RNA was cross-linked with UV at 1200 × 100 μJ/cm2 and the membrane was washed in 50 mM Tris pH 8.0 for 20 min at 45°C. Prehybridization and hybridization were performed in NorthernMax buffer (Ambion) at 68°C (30 min and overnight respectively). 500 ng of DIG-labeled probe in 10 mL were used for hybridization. The membrane was then washed with 2X SSC 0.1% SDS twice 30 min, then once 30 min and once 1 hr with 0.2X SSC 0.1% SDS at hybridization temperature. The membrane was the processed for DIG detection (hybridization with anti-DIG antibody, washing and luminescence detection) with the DIG luminescence detection kit (Roche), according to the manufacturer instructions. DIG-labeled probes were produced by in vitro transcription with DIG-RNA labeling mix (Roche) of PCR templates produced with the oligonucleotides ZNF609_C\_L_FW, ZNF609_C\_L_T7_RV used with both human and mouse cDNAs. Transcription with T7 RNA polymerase (Promega) was carried out overnight and the RNA was then loaded on 6% denaturing polyacrylamide gel, run for 1 hr in TB 1X at 100 V. The gel was stained with EtBr 1:10000 for 10 min, washed in ddH2O for 10 min and the bands were cut and resuspended in 500 μL of Na Acetate 0.3 M, 0.1 mM EDTA, 0.2% SDS pH 5.5. Elution was carried out overnight on a rotating wheel and the eluted RNA was purified by PCA and precipitated with 1 μL glycogen in 1 mL 100% Ethanol.

### RNaseq and circular RNA detection {#sec4.4.3}

Illumina TruSeq library preparation was performed by Istituto di Genomica Applicata (Udine, Italy) from 1 μg of total RNA, depleted of ribosomal RNA with Ribominus technology (Life Technologies). For each sample, 20-40 million 100bp long paired-end reads were collected for each sample (GEO: [GSE70389](ncbi-geo:GSE70389){#intref0045}), then trimmed and analyzed as reported in [QUANTIFICATION AND STATISTICAL ANALYSIS](#sec4.5){ref-type="sec"}, section "*RNAseq analyses*."

### Cell fractionation {#sec4.4.4}

Nuclear/cytoplasmic fractionation of human and mouse cells was performed according to [@bib28] as follows: cells (1 × 106) were washed with PBS and immediately lysed on ice with 500 μL of cytoplasmic lysis buffer (140 mM NaCl, 1.5 mM MgCl2, 10 mM Tris pH 7.5, 0.5% NP40) for 5 min. After scraping the cells and placing them in a 2 mL collection tube, 500 μL of a sucrose cushion (same as lysis buffer with 12% Sucrose) was gently pipetted to the bottom of the tube. Sample was centrifuged 10 min at 12000 x g. Supernatant and pellet were then separately resuspended in 1 mL of Qiazol, while sucrose was discarded. RNA extraction was carried out as described above.

Cytoplasm fractionations on sucrose gradients were performed as follows: 5x106 cells were lysed 5 min on ice with 500 μL of TNM (10 mM Tris pH 7.5, 10mM NaCl, 10 mM MgCl2) lysis buffer supplemented with 10 mg/ml cycloheximide, 1X PIC (Complete, EDTA free, Roche) and 1X RNase guard (Thermo Scientific), then spinned 2 min at 15000 x g for discarding nuclear pellets. Samples were centrifuged on 9 mL 15%--45% sucrose gradient at 38000 rpm with a SW41 rotor (Beckman) for 1 hr 30 min at 4°C. Fractions were collected with a Bio-logic LP (Biorad), 1 pg of a spike-in DNA as internal control was added to each fraction, together with 10 μg of glycogen, 100 μg of Proteinase K (Roche) and 40 μL of SDS. Samples were left 1 hr at 37°C and RNA was purified by PCA extraction and precipitated with isopropanol. DNA spike-in was produced amplifying the multiple cloning site from pcDNA3.1(-) (Life technologies).

For puromycin treatments, medium was replaced 3 hr before lysis with 1 mM puromycin containing- medium.

### Western blots {#sec4.4.5}

Cells were harvested with 50-100 μL of Protein Extraction Buffer (100 mM Tris pH 7.5, EDTA 1 mM, SDS 2%, PIC 1X (Complete, EDTA free, Roche) and incubated 20 min on ice, centrifuged at 15000 x g for 15 min at 4°C. Proteins (15-30 μg) were loaded on 4%--12% bis-tris-acrylamide gel (Life technologies) and transferred to a nitrocellulose membrane. The membrane was blocked in 5% milk and hybridized with the following antibodies, depending on the experiment.

FLAG protein sequence was detected by WB through F1804-1MG monoclonal anti-Flag M2 (Sigma-Aldrich).

Actinin and GAPDH were detected by WB through polyclonal anti-Actinin (H-300) sc-15335 (Santa Cruz Biotechnology) and monoclonal anti-GAPDH (6C5) sc-32233 (Santa Cruz Biotechnology), respectively.

### Immunofluorescence {#sec4.4.6}

Cells were washed twice in 100 mL PBS, fixed with 100 μL of 4% paraformaldehyde for 15 min at room temperature, washed twice with 100 μL of PBS, permeabilized and blocked with 100 μL of PBS with 0.2% Triton X-100 and 1% goat serum, incubated with 50 μL of in-house made anti-myogenin/anti-myosin antibody (available upon request), washed twice in PBS, incubated with 50 μL anti-mouse Cy3/AlexaFluor488 secondary antibody diluted 1:300 in PBS-DAPI and finally washed twice in PBS. Acquisition for image-based phenotypic analysis was performed with a widefield Nikon TiE Microscope equipped with a Lumencor SpectraX LED light source and PerfectFocus 3; 4 × and 10 × objectives were used (Nikon Instruments). For image analysis see [QUANTIFICATION AND STATISTICAL ANALYSIS](#sec4.5){ref-type="sec"}, section "*Image Analysis*."

For BrdU staining, we used 5-Bromo-2′-deoxy-uridine Labeling and Detection kit I (Roche). Labeling reagent was added to the cell culture medium (diluted 1:1000) 3 hr before fixation (human primary myoblasts) or 15' before fixation (C~2~C~12~), then cells were fixed with a solution made of 7 parts of ethanol and 3 parts of 50mM glycine at pH 2.0 for 20 min at --20°C. Cells were then washed twice with PBS and incubated for 1 hr at room temperature with 30 μL of antibody anti-BrdU diluted 1:10 in PBS. Cells were again washed twice and incubated for 30 min with anti-mouse Cy3/AlexaFluor488 secondary antibody diluted 1:300 in PBS-DAPI and finally washed twice in PBS. We took 4 pictures of each well with a Zeiss AXIO Observer A.1 with a 10X objective, both in the DAPI and Cy3 channels. For BrdU image analysis see [QUANTIFICATION AND STATISTICAL ANALYSIS](#sec4.5){ref-type="sec"}, section "*Image Analysis*."

For immunofluorescence of p-lin3xF-transfected cells, they were fixed in 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA) in PBS for 20 min at 4°C. Cells were then washed in PBS and permeabilized and blocked with 0.2%Triton X-100 /0,2% BSA in PBS for 20 min at room temperature. Subsequently, cells were processed for immunostaining with anti-FLAG M2 primary antibody (Sigma Aldrich) diluted 1:1000 in 0,2% BSA/1% Goat Serum/PBS for 16h at 4°C. Cells were then incubated with secondary antibody (Goat anti-Mouse IgG Cy3-conjugated, Jackson ImmunoResearch, West Grove, PA) diluted 1:500 in 1% Goat Serum/PBS for 45 min at room temperature. Finally, after extensive washing, DAPI (Sigma-Aldrich) was used to label nuclei and the coverlips were mounted in ProLong Diamond reagent (ThermoFischer Scientific). Samples were imaged on an Olympus IX73 inverted microscope equipped with Confocal Imager CREST X-LIGHT spinning disk, a CoolSNAP Myo CCD camera (Photometrics) and a Lumencor Spectra X LED illumination. The images were acquired using a LUCPlanFLN 20X objective (NA 0,45) and a UPLANSApo 60 X oil objective (NA 1.35) and collected with MetaMorph software (Molecular Devices). Stacks of images were taken automatically with 0,2 microns between the Z-slices. All Z stacks were processed with ImageJ software and merged with maximum intensity projection.

### Protein IP and mass spec {#sec4.4.7}

Cells were trypsinized and pelleted at 500 g for 5 min, washed in PBS and lysed in an equal volume to the cell pellet of lysis buffer (250 mM NaCl, 50 mM Tris pH 8, 5 mM EDTA, 0.8% NP40, 1 mM DTT, 5% glycerol, 50 mM NaF) with 20 strokes in a dounce homogenizer. Lysates were left on ice for 5 min and centrifuged at 15000 g for 10 min. Protein concentration of the supernatant was then measured by Bradford assay and a volume containing 5-10 mg of proteins was diluted 1:2 in dilution buffer (50 mM Tris pH 8, 5% glycerol). Fifty μl of protein G-coupled dynabeads (immunoprecipitation kit, Invitrogen) were washed in binding buffer (form the kit), resuspended in 200 μL of binding buffer containing 10 μg of anti- FLAG M2 antibody (Sigma-Aldrich Aldrich) and left rotating on a wheel for 1 hr at 4°C. Beads were then washed in binding buffer and incubated with the diluted lysates in a final volume of 600-800 μl. The binding was carried out at 4°C with the samples rotating on a wheel. Beads were then washed 3 times with low salt wash buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1mM EDTA, 0.25% NP40, 5% glycerol), 2 times in high salt wash buffer (same as low salt with 300 mM NaCl) and once in PBS. Samples were eluted with 20 □l Elution buffer (from the kit) and 10 μL LDS sample buffer (Invitrogen). Proteins were run on a 4%--12% polyacrylamide gel for 1 hr at 160 V and bands were cut according to the protein marker between 30 and 40 KDa. Bands were stored at 4°C in 300 μL H2O and sent for mass spectrometry analysis to the proteomic platform at IGBMC - Strasbourg, where they were digested with trypsin and analyzed according to their standard mass spectrometry pipeline.

### m6A IP {#sec4.4.8}

Cells were washed twice with PBSand lysed with 2ml of Qiazol (QIAGEN). The RNA was extracted according to Qiazol protocol. The m6A RIP was performed according to [@bib13] as follow: a volume containing 100 μg of RNA was diluted in a final volume of 300 mL with IPP buffer (10 mM Tris pH 7.4,150 Mm NaCl, 0.1% NP-40) containing 10 μg of anti-m6A antibody and incubated for 2 hr at 4°C.

The mixture was then immunoprecipitated by incubation with 50 μL of G-coupled dynabeads (immunoprecipitation kit, Invitrogen) at 4°C for an additional 2 hr.

Beads were then washed 5 times with IPP buffer and resuspended in 500 μL of Qiazol.

RNA was extracted according to Qiazol protocol and analyzed by qRT-PCR. Beads-only and isotypic IgG-coupled-beads were used as negative controls.

### Genome editing with Crispr/Cas9 {#sec4.4.9}

The insertion of a 3xFLAG coding sequence at position 3 of the Zfp 609 exon 2, immediately before the stop codon, was obtained in mouse embryonic stem cells by homology-directed repair of a Crispr/Cas9-induced DNA break. A guide RNA targeting the beginning of Zfp 609 exon 2 was designed with CRISPR design (<http://crispr.mit.edu>) and cloned in a px330 vector (see *Plasmid Construction* section). As a DNA donor, both a ssDNA oligo (ssDNA donor) and a plasmid donor carrying the same sequence plus 800 nt of homology upstream and downstream were used. Transfection of 500 ng of donor DNA plus 500 ng of px330 was performed in mES cells with 2 μL of lipofectamine 2000. After 48 hr, cells were split and a half was used for gDNA extraction and genotyping. gDNA was extracted with Real Genomics Genomic DNA extraction kit. Oligos crispr-A, B and C were used for amplifying the WT and recombinant alleles ([Figure S6](#mmc1){ref-type="supplementary-material"}D) on control cells and transfected cells. PCR products were Sanger sequenced and the plasmid donor-transfected cells resulted positive for the insertion. We diluted trypsinized cells at 0.5 cells/well in two 96 wells, and recovered a total of 20 colonies with the plasmid donor-transfected cells. Colonies were split after 10 days and half of each was grouped producing 3 pools, which were separately genotyped. Pool \#2 appeared positive, therefore the single colonies were further scrutinized and only one positive clone was identified (named "F/D," [Figures S6](#mmc1){ref-type="supplementary-material"}E and S6F).

### Plasmid construction {#sec4.4.10}

p-circ and p-circ-3xF were kindly provided by Hung Ho Xuan and Gunter Meister. Briefly, p-circ was produced by cloning the circZNF609 sequence in the circRNA mini vector ZKSCAN1 ([@bib26]), addgene \#60649) and p-circ-3xF was derived by inserting a 3xFLAG-coding sequence (GACTACAAAGACCATGACGGTGATTATAAAGATCATGACATCGATTACAAGGATGACGATGA CAAG) immediately upstream of the TAA codon present at position 3 in the circRNA sequence. We obtained the Δ1 derivative through inverse PCR on the p-circ-3XF vector with noATG1-ZNF609_FW and noATG1-ZNF609_RV oligonucleotides, while the Δ2 with noATG2-ZNF609_FW and noATG2- ZNF609_RV, the p-STOP2 with STOP2_fw and noATG2-ZNF609_RV on the p-circ-3xF template. The Δ1-2 was produced with an inverse PCR with noATG1-ZNF609_FW and noATG1- ZNF609_RV on the Δ2 template.

The p-lin-3xF vector was produced by inserting an amplicon obtained with pZNF_FW and pZNF_RV oligonucleotides from C~2~C~12~ gDNA using the In-Fusion HD Cloning Kit (Clontech) into pcDNA3.1- (Invitrogen), digested with EcoRI and NheI. The 3xFLAG tag was then inserted into the resulting vector through inverse PCR with 3xFlag_1/2FW and 3xFlag_1/2RV oligonucleotides. The oligonucleotides (Flag_zfp_guide2_FW and Flag_zfp_guide2_RV) encoding the Cas9 guide RNA were annealed and ligated in a BbsI-digested px330 vector (addgene \#42230, ([@bib10])).

Luciferase bicistronic reporter constructs were obtained from pGL3-Control vector (Promega) and pRL-TK vector (Promega). In order to get p-Luc empty vector, FLuc gene was isolated from pGL3-Control vector through the digestion with the restriction enzymes NheI and XbaI. This fragment was ligated to pRL-TK Vector digested with NheI. ZNF609 5′UTR was amplified with FW_5′UTR-circZNF609 and REV_5′UTR-circZNF609 oligonucleotides and cloned between the two luciferase genes in p-Luc empty vector, linearized by inverse PCR using FW_inversePCR-1 and RV_inversePCR-1 oligonucleotides. In order to obtain the UTR vector, eighty-four nucleotides upstream the 5′ splice junction of ZNF609 s exon were amplified with Fw_84ntZNF609 and Rev_84ntZNF609-2 oligonucleotides. The fragment was then inserted in the vector containing the ZNF609 5′UTR, linearized by inverse PCR with FW_inversePCR-2 and RV_inversePCR-1 oligonucleotides. In order to get UTR+In.β Glob vector, eighty- four nucleotides upstream the 5′ splice junction of ZNF609 s exon were amplified with Fw_84ntZNF609 and Rev_84ntZNF609 oligonucleotides and the second intron of Hbb-bs gene was amplified with Fw_b-globin-intr2 and Rev_b-globin-intr2 oligonucleotides. The vector containing only ZNF609 5′UTR was linearized as previously described, then the amplicons were cloned upstream ZNF609 5′UTR to obtain UTR+In.β Glob vector. ZNF609 UTR, 84-nucleotide fragment and Hbb-bs second intron were amplified from C~2~C~12~ gDNA by PCR. UTR+In.βGlob.D5′ss vector was obtained by inverse PCR from UTR+In.βGlob vector, using Luc_DeltaSplicing_FW and Luc_DeltaSplicing_RV oligonucleotides. In order to obtain UTR+In.-ZNF vector, 485 nucleotides from ZNF609 Intron 1-2 were amplified from mouse gDNA with FW_pLuc_In.Znf and RV_pLuc_In.Znf oligonucleotides. FW_pLuc_In.Znf contains forty nucleotides from the 5′ of ZNF609 Intron 2-3 right upstream the Intron 1-2 annealing sequence. This amplicon was inserted into UTR vector, which was previously linearized by inverse PCR, using FW_inversePCR-2 and RV_inversePCR-3 oligonucleotides. UTR+In.HPRT vector was obtained inserting HPRT Intron 8-9 into UTR vector, which was linearized by inverse PCR as previously described. HPRT Intron was amplified from mouse gDNA, using FW_pLuc_In.HPRT and RV_pLuc_In.HPRT oligonucleotides. In order to get MCS+In.βGlob vector, p-Luc empty vector was linearized by inverse PCR, as previously described. The second intron of Hbb-bs gene was amplified from UTR+In.βGlob vector, using FW_pLuc_In.bGlob_noUtr and RV_pLuc_In.bGlob_noUtr oligonucleotides. This amplicon was cloned in p-Luc vector. Then, this construct was linearized by inverse PCR, using FW_inversePCR-1 and RV_inversePCR-4 oligonucleotides. MCS sequence from pcDNA3.1(+) (Thermo Fisher Scientific) was amplified using FW_pLuc_MCS_noUtr and RV_pLuc_MCS_noUtr oligonucleotides. This amplicon was then cloned in the previous construct, in order to obtain MCS sequence downstream the βGlobin intron. EMCV IRES was amplified from pIRES2-EGFP plasmid (Clontech) with FW_IRES and RV_IRES oligonucleotides and cloned between luciferase genes (pLuc-EMCV-IRES) in p-Luc empty vector, linearized as previously described. UTR vector, UTR+In.βGlob vector, UTR+In.-ZNF vector, UTR+In.HPRT vector, MCS+In.βGlob vector and EMCV-IRES vector were realized with In-Fusion HD Cloning Kit (Clontech).

### Preparation of synthetic circRNAs {#sec4.4.11}

The linear version of the flagged circZNF609 transcript was obtained by in vitro transcription from a PCR-generated template (using p-circ-3xF as template and primers T7_ZNF_Flag_Fw and ZNF_Flag_Rv listed in [Table S2](#mmc3){ref-type="supplementary-material"}) in presence of T7 polymerase (Promega) following the manufacturer's instructions. Upon DNase treatment, The RNA was purified through polyacrylamide gel electrophoresis and the 5′-terminal triphosphate removed by treatment with Alkaline Phosphatase (Roche) in presence of RNase inhibitors. The RNA was then subjected to Ethanol precipitation upon the addition of 10 μg of glycogen (Roche). A phosphate group was then attached to the 5′-OH using ATP and T4 Polynucleotide kinase (BioLabs); the linear transcript carrying now 5′-phosphate and 3′-OH ends was subjected to Ethanol precipitation in presence of 10 μg of glycogen (Roche). Ligase reaction was carried out in a final volume of 100 μl, incubating the linear transcript at 95°C for 2 min followed by 5 min at 75°C in presence of 10% DMSO and equimolar amount of splint DNA (oligo in [Table S2](#mmc3){ref-type="supplementary-material"}). T4 RNA Ligase 1 (BioLabs), 1X T4 RNA Ligase Buffer, 10mM ATP and RNase inhibitor will be then added and the reaction was carried out at 16°C for 16 hr. The circularized RNA product was separated and purified from the linear transcript by polyacrylamide gel electrophoresis. Thirty nanograms of both circular and linear ZNF609 transcripts were subjected to RNase R treatment followed by qRT-PCR to assess the circularity of the gel-purified RNA molecules.

### Luciferase assay {#sec4.4.12}

pLuc empty vector, pLuc-UTR vector, pLuc-intr.-UTR vector, pLuc-EMCV-IRES vector and pLuc-intr.-UTR-D-Spl. vector were transfected in C~2~C~12~ cells as follows: 1 μL of lipofectamine 2000 was added to 100 μL of Optimem together with 500 ng of DNA, mixed and pipetted onto 50,000 pre-seeded cells in a 12 well plate. Medium was replaced 4 hr later and cells harvested for subsequent analyses after 48 hr.

Cells were harvested with PLB lysis buffer (Promega) and RLuc and FLuc activities were measured by Dual Glo luciferase assay (Promega) according to the manufacturer's protocol. A part of cell lysate was kept for RNA extraction and checked by RT-PCR with FLuc-pGL3control_FW and RLuc-pRLTK_RV oligonucleotides.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

### RNaseq analyses {#sec4.5.1}

For standard gene expression analysis, reads were mapped with TopHat, transcriptomes defined by Cufflinks and differential expression analyzed with Cuffdiff. For circRNA detection, paired-end reads were split and used separately as input to the following pipeline: reads were aligned to rRNA with Bowtie2, the remaining ones were mapped to hg19 or mm10 genome assemblies with Bowtie2. Reads that were left after these alignments were used by FindCirc, Memczak et al., 2013) for finding circRNAs. For quantitative analyses of circRNA regulation in human muscle differentiation, circRNAs with at least 5 reads in one sample were used. The total number of reads mapping to the head-to-tail splice junction was used for measuring circRNA expression level, while the mean of total reads mapping linearly to the same splice junction was used for measuring the abundance of the linear isoform. For comparing WT and DMD samples, circRNA expression level was normalized by dividing the reads mapping to the head-to-tail junctions by the total number of spliced reads identified for each sample by FindCirc.

After the circRNA detection process, all human circRNA events were annotated using bedtools to the Ensembl GRCh37 gene set. Annotation for gene structure features (CDS, UTR, Intron etc.) was performed with the R package CiRcus. For experimental validation, a subset of circRNAs were selected according to the following criteria: human circRNAs were first filtered for expression (at least 5 unique reads in one sample, at least 2 unique reads in its biological replicate), then sorted by the average fold change ratio between myotubes and myoblasts, then filtered for conservation (at least two unique reads in one sample in mouse of an overlapping circRNA). The ones with an absolute fold change ratio \> 2 were then sub-divided in 6 classes, according to the expression pattern of their cognate mRNA: (circRNA upregulated \> 2, downregulated \< 0.5) x (mRNA upregulated \> 2, downregulated \< 0.5, non regulated). Two or 3 of the top candidates were picked among each class, yelding a list of 16 circRNAs (ACVR2A, ANKIB1, ASH1L, ASPH1, BNC2, DCBLD2, MEF2A, MYL4, NEB, PMS1, PTP4A2, RTN4, RUNX1, SEPT9, SLC8A1, TMEFF1, TTN). Additional candidates were added according to their high expression level (HIPK3, ZNF292, BACH1, SPECC1, RTN4bis) and their high circular/linear ratio (ADAMTS6, CAMSAP1, CDYL, MED13L, ZFHX3, ZNF609, TTTY16). To such list, we added CRKL and QKI for the known role of their host genes in muscle differentiation. For each circRNA selection after sorting for fold change, expression level, circular/linear ratio, we manually inspected the RNaseq coverage and isoforms expression, and we manually excluded those situations that seemed too complicated for a validation experiment (too many isoforms, unexpected coverage, apparent *trans*-splicing events etc.). More details about bioinformatics analyses, all files and all scripts are available upon request.

### Image analysis {#sec4.5.2}

The acquired images were analyzed using two custom image analysis algorithms (available upon request), developed and executed in the Acapella software development/run-time environment (Perkin Elmer). Both algorithms used a Perkin Elmer proprietary algorithm on the DAPI staining for nuclei detection.

DAPI and MYOG staining at 48 hr were used to extract (for each siRNA treatment) the total cell number, the percentage of MYOG+ cells, and the average MYOG signal intensity. The DAPI&MYOG algorithm workflow can be summarized as follows: 1) nuclei detection (on DAPI channel); 2) MYOG signal intensity estimation (from Cy3 channel) and 3) MYOG ± nuclei classification. In the absence of a cytoplasmic marker, following the segmentation on DAPI, Voronoi tessellations were used to define local regions for each detected nucleus. Thus, foreground and background masks were defined to represent the nuclear area and its local background. These masks were further used to extract average DAPI and MYOG intensities for every nucleus. The standard deviations of MYOG intensity in the nuclei local background were estimated. The DAPI/MYOG signal intensity of every nucleus was defined as the difference between the DAPI/MYOG intensities of its local foreground and background. This local approach compensates for both intra- and inter-image spatial variability of illumination and minimizes possible errors in estimating DAPI/MYOG signal intensities over different wells (and fields). Following a similar local approach, and this time compensating for different inter-image noise level/content, the MYOG-positive and -negative classification was developed to use a local image adaptive threshold to apply on the MYOG signal intensity. For each analyzed image, the threshold was defined as 1.5^∗^median of all standard deviations of MYOG signal intensities of the local backgrounds of all nuclei detected in the current image. Then, each nucleus was classified as MYOG+ or MYOG- based on the comparison of its MYOG signal intensity and the current local image threshold (see the example Figure showing the MYOG-positive classification).

DAPI and MHC staining at 96 hr were used to extract (for each siRNA treatment) the total number of cells, the percentage of MHC-positive nuclei, and additional morphological parameters such as the fusion index and the number of nuclei per fiber. The algorithm workflow can be summarized as follows: 1) nuclei detection (on DAPI channel); 2) nuclei count correction procedure; 3) cytoplasm segmentation (on Red channel); 4) MHC signal intensity estimation (from the Red channel); 5) MHC-positive and -negative nuclei classification; 6) Red Cell/Fiber MHC+ nuclei classification. Prior to all analyses, a circular mask was applied on the images of all channels in order to remove vignetting.

Following DAPI segmentation of the nuclei, we applied a nuclei count correction procedure. This was required to overcome the issue of contiguous, 'syncytial-like' nuclei that were present in myotubes. The nuclei count correction procedure was developed based on a combination of some morphological features of the detected nuclei: the normalized nuclear area (with respect to the median of all nuclei area of the current image) and the nuclear axial length ratio (nucleus width/length). We could distinguish three classes of nuclei. First, all nuclei having a normalized area smaller than 1, which count as 1 nucleus each. A second class was defined by taking the integer of values derived after applying the floor function to nuclei with a normalized area greater than 1 (for example, nuclei with values between 2.0 and 2.99 were scored as 2, while those between 3.0 and 3.99 were scored as 3). Third, we defined a subclass with all nuclei having a normalized area between 1.5 and 2 and with an axial length \< 0.5 were counting as 2 nuclei each.

We used a Perkin Elmer proprietary algorithm to define the cytoplasmic area for each nucleus. The cytoplasmic area is assigned to the nuclei based on the signal in the Red channel. This was associated with two problems. First, because of the peculiar morphology of cells and fibers (cells have elongated shape, fibers appear stitched/clumpy and are multinucleated), individual cells/fibers were erroneously subdivided. Second, in some cases, the method attempted to assign cytoplasm to cells that, on visual inspection, had no signal in the Red channel.

Thus, we defined a population of 'cell' objects including a nuclear region (with one or more nuclei) and a cytoplasmic region. All the detected 'cell' objects that had a cytoplasmic/nuclear area smaller than one were removed from the cytoplasmic segmentation result, since they were potentially MHC-negative.

From the remaining population of cells, we defined a cellular mask (cytoplasm and nuclear areas) on which MHC-positive/negative nuclei classification was performed. All nuclei with at least one quarter of their area overlapping the cellular mask were classified as MHC-positive. All other nuclei were labeled as MHC-negative.

The Red Cell/Fiber classification was implemented using a work-around of the cytoplasm segmentation. The definition of a fiber was as follows: stitched/clumpy cells with multiple and short distanced nuclei (clusters). Red Cells were defined as elongated and mono-nucleate. We used the presence of nuclei clusters to differentiate between Red Cells and Fibers. Specifically, nuclei that were within 100 μm of each other were defined as being part of the same cluster. Thus, we used the morphological dilation operator (circular structuring element of 30 pixels diameter) on the nuclear mask given by all MHC-positive nuclei. The resulting 'dilated' mask was then intersected ('AND' operator) with the cellular mask to separate nuclei of neighboring Red Cells. This resulting binary image was used to define nuclei clusters by using connected component labeling ([@bib3]) and selecting only those components containing more than one MHC-positive nucleus. Finally, all MHC-positive nuclei belonging to nuclei clusters were labeled as 'Fiber nuclei'. Similarly, all those MHC-positive nuclei that were not part of a nuclear cluster are labeled as Red Cell nuclei. The result of this classification was transferred to the nuclei-associated 'cell' objects, and thus labeled as Fibers and Red Cells.

For each well, this algorithm reports a set of 8 parameters. The first four parameters are based on nuclei, namely, total number of (detected) nuclei, percentage of MHC-positive nuclei, percentage of MHC-positive Red-Cell nuclei, average number of nuclei per Fiber (estimated by the average number of nuclei per nuclei cluster). The following two parameters are cell area descriptors: the fraction of Red Cell area and the fraction of Fibers area. These fractions were estimated as the total area of Red Cells/Fibers with respect to the entire area of the analyzed image. Two additional parameters were implemented to better describe cellular phenotypes. The fusion index was defined as the fraction of total number of Fiber nuclei to the total number of detected nuclei. The maturation index was defined as the fraction of the total number of Fiber nuclei to the total number of MHC-positive nuclei. All raw images, segmentation results and scripts are available upon request.

BrdU images were analyzed manually by using ImageJ: tiff files were converted into binary images by setting a fixed threshold for both DAPI and BrdU signal intensity, merged edged of close nuclei were split through the Watershed plug-in and nuclei count was performed with the built-in particle analysis plug-in. Accepted nuclei dimension were set in a range corresponding to the second and third quartiles of all particles detected.

### Statistical Analyses {#sec4.5.3}

All experiments were repeated for at least 3 times unless differently stated in the legend; arithmetic means together with standard error are reported in all plots shown in this study unless differently stated in the legend. Statistical significance for comparisons of means was assessed by Student's t test for qRT-PCRs, luciferase assays and immunofluorescence-based screenings. Dedicated statistics were applied to RNaseq data analysis as specified in the legends. P values below 0.05 were marked by 1 asterisk, while 2 asterisks indicate a p value \< 0.02 and 3 asterisks a p value \< 0.01. When multiple comparisons were performed, p values were scaled according to the Bonferroni correction and then filtered for corrected p value \< 0.1.

Data and Software Availability {#sec4.6}
------------------------------

All software used in this manuscript is listed in the [Key Resources Table](#sec4.1){ref-type="sec"}. Additional dedicated scripts developed for this work are available upon request. The accession number for the sequences reported in this paper is GEO: [GSE70389](ncbi-geo:GSE70389){#intref0055}.
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![Identification of CircRNAs in Mammalian Myoblast Differentiation\
(A) Experimental and computational pipelines for the identification of circRNAs from human and mouse myoblasts (expressing MyoD and Myf5) and myotubes (expressing Myosin Heavy Chain \[MHC\] and Muscle Creatin Kinase \[CKM\]). Blue, rRNA and genomic reads; blue-red, reads across linear splice junctions; red, reads across back-splicing junctions.\
(B) Number of detected linear and circular splicing events per sample with bona fide circRNAs passing selection filters (see the [STAR Methods](#sec4){ref-type="sec"}). Samples are human primary and mouse C~2~C~12~ myoblasts (GM) and myotubes (DM) in two replicates (A and B).\
(C) Left panel: genomic annotation of circRNAs. Right panel: structural annotation of circRNAs mapping to coding regions is shown.\
(D) Overlap of unique circRNAs in human and mouse samples before and after (left and right) filtering for expression level higher than five unique reads in human samples.\
See also [Figure S1](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc2){ref-type="supplementary-material"}.](gr1){#fig1}

![Differential CircRNA Expression in Human Myoblast Differentiation and Disease\
(A) Scatterplots showing reads mapping to highly expressed circRNA junctions in two myoblast (GM, A and B, left) and myotube (DM, A and B, right) replicates.\
(B) Heatmap showing expression levels of selected circRNAs in WT and DMD myoblasts (GM, A and B) and myotubes (DM, A and B). Values are normalized as row *Z* scores.\
(C) Scatterplot showing circular/linear (C/L) ratio in GM versus DM, calculated as log2 of the number of reads mapping to a circular junction divided by the mean of reads mapping linearly at the same genomic coordinates.\
(D) Empirical cumulative distribution of the C/L ratio in GM (blue) and DM (red).\
(E) Scatterplot of fold change of reads mapping to circRNA junctions versus reads mapping to linear junctions at the same coordinates. Linear regression is shown in red. Black lines correspond to a fold change of 2.\
(F) Bar plot representing fold change of circRNA expression in myotubes versus myoblasts (DM/GM) grouped by differential expression of host gene according to Cuffdiff FPKMs. Two and three asterisks indicate a Wilcoxon-Mann-Whitney test-derived p value below 0.02 and 0.01, respectively. Up, upregulated genes; Eq, non-differentially expressed genes; down, downregulated genes (fold change \> 2).\
(G) Left panels: coverage plots of genomic loci of circ-BNC2 and circ-CDYL. Right panels: bar plots show reads mapping to circular (Circ) and linear (Lin) splice sites for circ-BNC2 and circ-CDYL in GM (blue bars) and DM (red bars).\
See also [Figure S2](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc2){ref-type="supplementary-material"}.](gr2){#fig2}

![CircRNA Knockdown followed by Phenotypic Screening in Human Primary Myoblasts\
(A) Experimental workflow of the phenotypic screening strategy.\
(B) Heatmap showing selected phenotypes in color scale after *Z* score normalization. High values are shown in blue while low values are shown in red. Each column indicates one phenotype and each row indicates one sample. The number of detected significant phenotypes is shown in red scale on the right.\
(C) Human primary myoblasts were treated with either a control scramble siRNA (si-SCR) or with siRNAs against circ-QKI (si-QKI \#1) and circ-BNC2 (si-BNC2 \#1) and induced to differentiate for 48 (upper panels) and 96 hr (lower panels). A representative immunofluorescence for MYOG and MHC together with DAPI staining is shown.\
(D) RNA levels measured by qRT-PCR of circ-QKI and circ-BNC2 in human control (WT) and Duchenne (DMD) myocytes. RNA measurements were performed from biological triplicates of two WT (light gray bars) and three DMD primary cell lines (dark gray bars).\
See also [Figure S3](#mmc1){ref-type="supplementary-material"} and [Table S3](#mmc4){ref-type="supplementary-material"}.](gr3){#fig3}

![Circ-ZNF609 Controls Myoblast Proliferation\
(A) Human myoblasts were treated with either a control siRNA (si-Scr) or with siRNAs against the circRNA indicated; cells were maintained in growth conditions. The color scale represents the percentage of BrdU-positive cells measured in triplicate.\
(B) Schematic representation of the siRNAs used for circ-ZNF609 phenotype validation. The siRNA targeting specifically the circRNA is shown in red (si-circ), the siRNA targeting both the circRNA and the linear mRNA is shown in green (si-ex2), and the siRNA targeting only the mRNA is shown in blue (si-mRNA).\
(C) Human primary myoblasts were treated with either a control scramble siRNA (si-Scr) or the siRNAs shown in (B). A representative immunofluorescence for BrdU is shown in red and DAPI staining is shown in blue.\
(D) Percentage of BrdU incorporation levels in cells treated as in (C).\
(E) RNA quantification by qRT-PCR of circ-ZNF609, ZNF609 mRNA, and two markers of cell-cycle progression (CDK1 and Cyclin A2) after treatment with the siRNAs as in (C).\
(F) Left panel: schematic representation of the DIG-labeled probe used for northern blot analysis together with its location on the circular and linear forms of ZNF609 RNAs. Right panel: northern blots on 20 μg total RNA from primary myoblasts treated with either siRNAs (si-Scr and si-circ) or RNase R (-- and +) are shown. The linear and the circular RNA forms are indicated aside the gels with the "--" and "o" symbols, respectively. As a control, northern blot was performed on 20 μg total RNA from myoblasts with the addition of 1 μg RNA from HeLa cells transfected with either an empty vector (mock) or a construct overexpressing circ-ZNF609 (p-circ). Each blot is shown in parallel to the EtBr staining of the agarose gel, where the migration of the 18S and 28S rRNAs is indicated.\
(G) RNA levels measured by qRT-PCR of circ-ZNF609 in human wild-type (WT) and Duchenne (DMD) myoblasts upon differentiation. RNA measurements were performed from biological duplicates of two WT and three DMD primary myoblasts. All values derive from three independent experiments unless differently stated. One asterisk indicates a Student's t test-derived p value \< 0.05, two asterisks indicate a p value \< 0.02, and three asterisks a p value \< 0.01. Bars show mean and SE.\
See also [Figure S4](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}

![Circ-ZNF609 RNA Is Associated with Polysomes\
(A) Schematic representation of the following: ZNF609 pre-mRNA (center), ZNF609 mRNA (above), and ZNF609 s exon (below) from which circ-ZNF609 (right) originates. The 5′ and 3′ UTRs are indicated by smaller boxes, while the coding region (CDS) is represented by larger boxes. Start and stop codons are shown in green and red, respectively.\
(B) Cytoplasmic extracts from proliferating human myoblasts, either untreated (native, black) or treated with puromycin (gray), were loaded on 15%--50% sucrose gradients. Absorbance at 253 nm was measured and fractions were collected. Fraction density decreases from left to right; the panels show one representative profile of three independent biological replicates. Individual fractions were analyzed by qRT-PCR and are represented as a percentage of total RNA in each fraction. Profiles are shown for circ-ZNF609 and ZNF609 mRNA. Circ-PMS1 and HPRT mRNA represent negative and positive controls, respectively.\
See also [Figure S5](#mmc1){ref-type="supplementary-material"}.](gr5){#fig5}

![Circ-ZNF609 Has Protein-Coding Activity\
(A) Schematic representation of the p-circ3xF construct. The second exon of the ZNF609 gene was cloned in a plasmid carrying inverted repeats (IRs) from the ZKSCAN1 gene (see the [STAR Methods](#sec4){ref-type="sec"}) in order to achieve circularization. A 3×FLAG tag was inserted upstream to the stop codon in order to obtain a flagged protein after circularization. Mutant derivatives with deleted ATGs are shown below. Start and stop codons are shown in green and red, respectively. A 3×FLAG-coding sequence is shown in blue.\
(B) Western blot analysis with an anti-FLAG antibody on proteins from HeLa (human) and N2a (mouse) cells transfected with p-circ3xF and its mutant derivatives. GAPDH was used as a loading control.\
(C) Western blot analysis with an anti-FLAG antibody on proteins from HeLa cells transfected with pcDNA, p-circ3xF, and its mutant derivative p-STOP2. ACTN was used as a loading control.\
(D) Schematic representation of the genome-editing approach for tagging the endogenous ZNF609 locus. Mouse embryonic stem cells were edited with homology-directed repair of a CRISPR/Cas9-induced double-strand break (DSB) with a DNA donor carrying a 3×FLAG-coding sequence (in blue) immediately upstream of the stop codon in exon 2. The edited cells were cultured and harvested for IP with an anti-FLAG antibody. The eluted proteins were run on SDS-PAGE (size selected between 30 and 40 kDa) and subjected to mass spectrometry.\
(E) Individual peptides detected by mass-spec are depicted in orange at their mapping position onto the protein sequence. Mass-spec data are shown for the overexpression of the linear ORF (see [Figure S6](#mmc1){ref-type="supplementary-material"}A) by p-lin3xF (top), overexpression of the circular RNA from p-circ3xF (middle), and expression from the edited endogenous locus (bottom).\
(F) Representative western blot analysis with an anti-FLAG antibody on proteins from HeLa cells transfected with either pcDNA or p-circ3xF in normal (CTR) or heat shock conditions. Circ-ZNF609 RNA levels were the same in both conditions (data not shown). As controls of the heat shock response, blots were hybridized with Hsp70 and phosphorylated eIF2 alpha antibodies. Actinin was used as a loading control.\
(G) Schematic representation of the luciferase bicistronic constructs used. The SV40 promoter drives the transcription of Firefly (F-Luc) and Renilla (R-Luc) luciferase-coding regions in the control construct (p-Luc). The spacer of p-Luc was substituted with the IRES sequence of the Encephalomyocarditis virus (EMCV) or 80 nt from the 3′ portion of the second exon fused to the UTR of circ-ZNF609 (UTR). From UTR, additional constructs were raised carrying one intron from the ZNF609, HPRT, and β-globin (UTR-in ZNF/HPRT/βGlob.) genes. From UTR-in-βGlob. two other constructs were derived as follows: UTR-inΔss has a deletion of the 5′ splice site, while MCS-inβGlob. carries an unrelated sequence in place of the UTR.\
(H) Luciferase activity derived from cells transfected with the constructs described in (G). Values from three independent experiments are expressed as ratio of Renilla versus Firefly activities. Three asterisks represent a Student's t test-derived p value \< 0.01 between the value of each sample and the empty vector. Bars show mean and SE.\
See also [Figure S6](#mmc1){ref-type="supplementary-material"}.](gr6){#fig6}

###### 

The Selected 31 CircRNAs and Summary of Their Experimental Validation

  Human CircRNAs in Human Myoblasts Cells                                                                                                            
  ----------------------------------------- ---------------- ----------- ----------- ------------------------------------ ------------ ------------- -------------
  Circ-ACVR2A                               chr2             148653869   148657467   0, 3, 10, 7                          yes          yes           cyt
  Circ-ADAMTS6                              chr5             64747301    64769779    37, 34, 0, 5                         yes          yes           cyt
  Circ-ANKIB1                               chr7             91924202    91957214    0, 3, 6, 6                           yes          yes           cyt
  Circ-ASH1L                                chr1             155408117   155408859   6, 5, 2, 0                           yes          yes           cyt
  Circ-ASPH                                 chr8             62531536    62566219    3, 0, 2, 0                           yes          yes           cyt
  Circ-BACH1                                chr21            30693541    30702014    11, 12, 9, 4                         yes          yes           cyt
  Circ-BNC2                                 Chr9             16435552    16437522    0, 0, 8, 7                           yes          yes           cyt
  Circ-CAMSAP1                              Chr9             138773478   138774924   15, 8, 16, 17                        yes          yes           cyt
  Circ-CDYL                                 Chr6             4891946     4892613     10, 12, 18, 21                       yes          yes           cyt
  Circ-CRKL                                 Chr22            21288066    21288532    0, 2, 10, 8                          yes          yes           cyt
  Circ-DCBLD2                               chr3             98568304    98600611    27, 31, 3, 4                         yes          yes           cyt
  Circ-HIPK3                                Chr11            33307958    33309057    88, 82, 90, 93                       yes          yes           cyt
  Circ-MED13L                               Chr12            116668337   116675510   10, 7, 5, 16                         yes          yes           cyt
  Circ-MEF2A                                Chr15            100211527   100215663   0, 0, 2, 0                           yes          yes           cyt
  Circ-MYL4                                 Chr17            45297314    45297419    0, 0, 4, 8                           no           N/A           N/A
  Circ-NEB                                  chr2             152544139   152550950   0, 0, 18, 34                         yes          no            N/A
  Circ-PMS1                                 chr2             190656515   190682906   3, 0, 7, 3                           yes          yes           cyt
  Circ-PTP4A2                               chr1             32381495    32385259    6, 12, 9, 15                         yes          yes           cyt
  Circ-QKI                                  chr6             163876310   163956157   0, 0, 7, 8                           yes          yes           cyt
  Circ-RTN4                                 chr2             55252221    55255356    0, 0, 4, 6                           yes          yes           cyt
  Circ-RTN4bis                              chr2             55209650    55214834    10, 13, 22, 20                       yes          yes           cyt
  Circ-RUNX1                                Chr21            36206706    36231875    0, 2, 9, 7                           yes          yes           cyt
  Circ-SEPT9                                chr17            75398140    75398785    3, 0, 7, 3                           yes          yes           cyt
  Circ-SLC8A1                               chr2             40655612    40657444    71, 53, 12, 13                       yes          yes           cyt
  Circ-SPECC1                               chr17            20107645    20109225    7, 5, 12, 6                          yes          yes           cyt
  Circ-TMEFF1                               chr9             103261046   103279053   3, 0, 5, 7                           yes          yes           cyt
  Circ-TTN                                  chr2             179557223   179558735   0, 0, 2, 3                           yes          yes           cyt
  Circ-ZFHX3                                chr16            72984367    72994093    3, 2, 2, 0                           yes          yes           cyt
  Circ-ZNF292                               chr6             87920169    87928449    8, 11, 11, 6                         yes          yes           cyt
  Circ-ZNF609                               chr15            64791491    64792365    13, 4, 12, 8                         yes          yes           cyt
  Circ-TTTY16                               chrY             7565120     7567528     2, 0, 0, 2                           yes          yes           cyt
                                                                                                                                                     
  **Mouse CircRNAs in C~2~C~12~ Cells**                                                                                                              
                                                                                                                                                     
  **CircRNA**                               **Chromosome**   **Start**   **End**     **Reads (GM A, GM B, DM A, DM B)**   **RT-PCR**   **RNase R**   **Cyt/Nuc**
                                                                                                                                                     
  Circ-Acvr2a                               chr2             48870288    48873473    0, 0, 4, 6                           yes          yes           cyt
  Circ-Adamts6                              chr13            104294446   104314383   0, 2, 2, 5                           yes          yes           cyt
  Circ-Ankib1                               chr5             3747020     3772787     0, 4, 14, 13                         yes          yes           cyt
  Circ-Ash1l                                chr3             89001772    89007877    0, 0, 5, 3                           yes          yes           cyt
  Circ-Asph                                 chr4             9583811     9610938     0, 0, 5, 4                           yes          yes           cyt
  Circ-Bach1                                chr16            87715330    87722608    2, 0, 0, 2                           yes          yes           cyt
  Circ-Bnc2                                 chr4             84291692    84293662    2, 2, 12, 19                         yes          yes           cyt
  Circ-Camsap1                              chr2             25965662    25966948    0, 0, 8, 7                           yes          yes           cyt
  Circ-Cdyl                                 chr13            35815908    35816575    7, 5, 19, 25                         yes          yes           cyt
  Circ-Crkl                                 chr16            17468892    17469358    0, 0, 1, 0                           yes          yes           cyt
  Circ_Dcbld2                               chr16            58424560    58433463    5, 10, 2, 6                          yes          yes           cyt
  Circ-Hipk3                                chr2             104470748   104471847   5, 7, 43, 42                         yes          yes           cyt
  Circ-Med13l                               chr5             118593332   118593570   6, 4, 17, 27                         yes          yes           cyt
  Circ-Mef2a                                chr7             67264864    67268400    0, 0, 8, 3                           yes          yes           cyt
  Circ-Myl4                                 chr11            104584022   104584127   0, 0, 6, 3                           yes          yes           cyt
  Circ-Neb                                  chr2             52299476    52305391    0, 0, 39, 37                         yes          no            N/A
  Circ-Pms1                                 chr1             53256628    53282092    0, 4, 6, 8                           yes          yes           cyt
  Circ-Ptp4a2                               chr4             129838977   129846539   2, 0, 0, 0                           yes          yes           cyt
  Circ-Qk                                   chr17            10238892    10282981    0, 0, 2, 0                           yes          yes           cyt
  Circ-Rtn4                                 chr11            29705534    29708770    2, 3, 6, 13                          yes          yes           cyt
  Circ-RTN4bis                              chr11            29733632    29736498    0, 0, 0, 2                           yes          yes           cyt
  Circ-Runx1                                chr16            92644153    92668812    0, 0, 5, 6                           yes          yes           cyt
  Circ-Sept9                                chr11            117290397   117291036   2, 2, 9, 9                           yes          yes           cyt
  Circ-Slc8a1                               chr17            81647808    81649638    0, 0, 12, 16                         yes          yes           cyt
  Circ-Specc1                               chr11            62117699    62119282    0, 2, 0, 0                           yes          yes           cyt
  Circ-Tmeff1                               chr4             48604580    48617331    0, 2, 6, 5                           yes          yes           cyt
  Circ-Ttn                                  chr2             76766305    76791371    0, 0, 3, 7                           yes          yes           cyt
  Circ-Zfhx3                                chr8             108792201   108800691   2,3,4,3                              yes          yes           cyt
  Circ-Zfp292                               chr4             34839331    34839986    0,0,12,14                            yes          yes           cyt
  Circ-Zfp609                               chr9             65794621    65795495    0,0,10,7                             yes          yes           cyt
  Circ-Ttty16                               N/A              N/A         N/A         N/A                                  N/A          N/A           N/A

Columns contain: gene name, genomic coordinates (hg19 for human and mm10 for mouse) of the head-to-tail splice junction, number of reads mapped to the splice junction in human or mouse myoblasts (GM A and GM B) and myotubes (DM A and DM B), RT-PCR validation (yes if bands of the expected size were obtained and no if not), RNase R resistance (yes if the fraction of recovery after RNase R treatment of the circular form was significantly higher than for the linear form and no if not), and subcellular localization. "N/A" applies to the murine circ-Ttty16, where it was not detected because the host gene is located in the Y chromosome, which is missing in C~2~C~12~ cells. cyt, cytoplasm; nuc, nucleus.

[^1]: Lead Contact
